TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vaxart ( (VXRT) ) has shared an announcement.
On November 4, 2025, Vaxart entered into an exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart’s investigational oral COVID-19 vaccine candidate. Under this agreement, Dynavax will pay Vaxart an upfront fee of $25 million and make a $5 million equity investment. Vaxart will continue to lead the development through Phase 2b, after which Dynavax may assume responsibility for further development. If Dynavax proceeds, Vaxart could receive additional milestone payments and royalties. This collaboration aims to leverage Vaxart’s oral vaccine platform and Dynavax’s commercial expertise to provide easily administered COVID-19 vaccine options, potentially enhancing patient acceptance and distribution.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall stock score is primarily impacted by its strong revenue growth but significant profitability challenges. The technical analysis suggests a bearish trend, and valuation metrics are weak due to ongoing losses. The earnings call provided some positive developments but also highlighted significant operational challenges.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart is a clinical-stage biotechnology company that develops oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, eliminating the risk of needle-stick injury. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).
Average Trading Volume: 526,453
Technical Sentiment Signal: Sell
Current Market Cap: $76.69M
For detailed information about VXRT stock, go to TipRanks’ Stock Analysis page.